{"nctId":"NCT01324999","briefTitle":"Tadalafil for Sarcoidosis Associated Pulmonary Hypertension","startDateStruct":{"date":"2011-03"},"conditions":["Pulmonary Hypertension"],"count":12,"armGroups":[{"label":"Sarcoid Associated Pulm. Hypertension","type":"EXPERIMENTAL","interventionNames":["Drug: Tadalafil"]}],"interventions":[{"name":"Tadalafil","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Biopsy proven sarcoidosis\n* Mean pulmonary artery pressure \\> 25 mmHg at rest or greater than 30 mmHg with exercise by right heart catheterization within 1 year prior to entry into study\n* Pulmonary capillary wedge pressure ≤ 15 mmHg\n* PVR values ≥ 3.0 Woods units\n* Forced vital capacity (FVC) \\> 40% predicted\n* Forced expiratory volume in 1 second (FEV1) \\> 40% predicted\n* WHO functional class II or III\n* Stable sarcoidosis treatment regimen for three months prior to entry into study\n* 6 minute walk distance between 150-450 meters\n* Stable dose of antihypertensive medications\n* On no other medication to treat PAH (sildenafil, vardenafil, treprostinil, epoprostenol, iloprost, bosentan, ambrisentan) within one month prior to enrollment and during duration of the study\n* Non-pregnant females\n\nExclusion Criteria:\n\n* Exercise limitation related to a non-cardiopulmonary reason (e.g. arthritis)\n* Severe systemic hypertension \\> 170/95\n* Severe systemic hypotension \\< 90/50\n* History of priapism\n* Patients with congestive heart failure (left ventricular dysfunction) LVEF \\< 45% by echocardiogram\n* Anticipation by the investigator for escalation in sarcoidosis treatment during the course of the study\n* Pulmonary hypertension related to etiology other than sarcoidosis (i.e. HIV, scleroderma, chronic thromboemboli)\n* Use within 1 month of an sildenafil or vardenafil\n* WHO functional class IV status\n* Patients with severe other organ disease felt by investigators to impact on survival during the course of the study\n* Subjects with liver function abnormalities (ALT or AST \\> 3 times the upper limit of normal at screening or at baseline) or chronic liver disease\n* Advanced kidney failure (GFR \\< 30 ml/min at screening or at baseline)\n* History of hypersensitivity reaction or adverse effect related to tadalafil\n* Pregnant or lactating women\n* Concomitant use of nitrates (any form) either regularly or intermittently\n* Concomitant use of potent CYP3A inhibitors (eg, ritonavir, ketoconazole, itraconazole)\n* Any additional contraindications and precautions specified in the package inserts for Tadalafil (Adcirca) not listed above","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"6 Minute Walk Distance","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"419.1","spread":"170.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"418.1","spread":"143.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"436.5","spread":"178.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"377.1","spread":"140.9"}]}]}]},{"type":"SECONDARY","title":"Resting Oxygen Saturation","description":"Percent oxygen saturation of hemoglobin as measured by pulse oximetry in the resting state.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.5","spread":"1.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.2","spread":"2.6"}]}]}]},{"type":"SECONDARY","title":"Oxygen Desaturation During 6 Minute Walk Test","description":"Change (decrease) in oxygen saturation from start of 6 minute walk to nadir during the 6 minute walk test","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":"6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":"9"}]}]}]},{"type":"SECONDARY","title":"Maximum Borg Dyspnea Score During 6 Minute Walk Test","description":"The modified Borg scale consists of a vertical scale labelled 0 to10 with corresponding verbal expressions of progressively increasing sensation (shortness of breath) intensity. 0 represents no dyspnea, and 10 is the highest level of perceived dyspnea.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"2.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":"2.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"2.3"}]}]}]},{"type":"SECONDARY","title":"Brain Natriuretic Peptide Level","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.8","spread":"89.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.3","spread":"46.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.5","spread":"51.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.6","spread":"49.7"}]}]}]},{"type":"SECONDARY","title":"Short Form-36 Global Score","description":"SF- 36 investigates the standard of quality of life through a general health assessment and not specific to a particular disease, age or treatment group. It is a 36-item questionnaire measuring 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health). Each domain score ranges from 0 (worst) to 100 (best), with higher scores reflecting better health-related functional status. The global score is determined by taking an average of the individual domain scores. The global score range is from 0 (worst) to 100 (best).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.5","spread":"5.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.7","spread":"6.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.2","spread":"6.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.9","spread":"8.5"}]}]}]},{"type":"SECONDARY","title":"St. George's Respiratory Questionnaire (SGRQ) Score","description":"The SGRQ ranges from 0 (no impairment of quality of life) to 100 (highest impairment of quality of life)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.5","spread":"15.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.1","spread":"18.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.3","spread":"15.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.1","spread":"15.2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Change in WHO Functional Class (WHO FC)","description":"The WHO functional classification ranges from I (patient's disease does not affect daily activities) to IV (patient's disease causes severe impairment). Higher scores indicate more severe impairment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":12},"commonTop":["Headache","Joint pain","Herpes zoster","Influenza/pneumonia"]}}}